Sunteng

Sunteng is a Beijing-based biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform to target infectious diseases, oncology, and rare genetic disorders. Their lead programs include mRNA vaccines for COVID-19 and other respiratory viruses, designed to provide robust immune responses. Sunteng aims to overcome technical bottlenecks in nucleic acid delivery through its integrated R&D and manufacturing capabilities. The company is part of the emerging wave of Chinese biotech firms focused on establishing independent intellectual property in advanced genetic medicine. Their approach combines high-efficiency translation with low-toxicity delivery systems to improve patient outcomes.